Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts

REFERENCES

• Koob G F. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 2000; 909: 170–185
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao L Y, Epstein D H, Zhang X L, Lu L. Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers. Pharmacol Biochem Behav 2007; 87(1)141–145
   PubMed Web of Science ®Google Scholar
• Cohen L J, Gertmenian-King E, Kunik L, Weaver C, London E D, Galynker I. Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates. Acta Psychiatr Scand 2005; 112(2)149–158
   PubMed Web of Science ®Google Scholar
• O'Connor P G, Fiellin D A. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000; 133(1)40–54
   PubMed Web of Science ®Google Scholar
• Nestler E J, Aghajanian G K. Molecular and cellular basis of addiction. Science 1997; 278(5335)58–63
   PubMed Web of Science ®Google Scholar
• Goeders N E. Stress and cocaine addiction. J Pharmacol Exp Ther 2002; 301(3)785–789
   PubMed Web of Science ®Google Scholar
• Kreek M J, Koob G F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998; 51(1–2)23–47
   PubMed Web of Science ®Google Scholar
• Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology (Berl) 2001; 158(4)343–359
   PubMed Web of Science ®Google Scholar
• Sinha R, Talih M, Malison R, Cooney N, Anderson G M, Kreek M J. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology (Berl) 2003; 170(1)62–72
   PubMed Web of Science ®Google Scholar
• Sarnyai Z, Shaham Y, Heinrichs S C. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001; 53(2)209–243
   PubMed Web of Science ®Google Scholar
• Piazza P V, Le Moal M L. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu Rev Pharmacol Toxicol 1996; 36: 359–378
   PubMed Web of Science ®Google Scholar
• Koob G, Kreek M J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 2007; 164(8)1149–1159
   PubMed Web of Science ®Google Scholar
• Kreek M J, Wardlaw S L, Hartman N, Raghunath J, Friedman J, Schneider B, Frantz A G. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci 1983; 33(Suppl 1)409–411
   PubMed Web of Science ®Google Scholar
• Cushman P, Jr., Kreek M J. Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin. N Y State J Med 1974; 74(11)1970–1973
   PubMedGoogle Scholar
• Cami J, Gilabert M, San L, de la Torre R. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br J Addict 1992; 87(8)1145–1151
   PubMedGoogle Scholar
• Bearn J, Buntwal N, Papadopoulos A, Checkley S. Salivary cortisol during opiate dependence and withdrawal. Addict Biol 2001; 6(2)157–162
   PubMed Web of Science ®Google Scholar
• Shalev U, Yap J, Shaham Y. Leptin attenuates acute food deprivation-induced relapse to heroin seeking. J Neurosci 2001; 21(4)RC129
   PubMed Web of Science ®Google Scholar
• Kiefer F, Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addict Biol 2004; 9(3–4)205–212
   PubMed Web of Science ®Google Scholar
• Kosten T R, Markou A, Koob G F. Depression and stimulant dependence: neurobiology and pharmacotherapy. J Nerv Ment Dis 1998; 186(12)737–745
   PubMed Web of Science ®Google Scholar
• Gil-Ad I, Bar-Yoseph J, Smadja Y, Zohar M, Laron Z. Effect of clonidine on plasma beta-endorphin, cortisol and growth hormone secretion in opiate-addicted subjects. Isr J Med Sci 1985; 21(7)601–604
   PubMedGoogle Scholar
• O'Brien C P, Terenius L Y, Nyberg F, McLellan A T, Eriksson I. Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biol Psychiatry 1988; 24(6)649–662
   PubMed Web of Science ®Google Scholar
• Housova J, Wilczek H, Haluzik M M, Kremen J, Krizova J, Haluzik M. Adipocyte-derived hormones in heroin addicts: The influence of methadone maintenance treatment. Physiol Res 2005; 54(1)73–78
   PubMed Web of Science ®Google Scholar
• Wilczek H, Haluzik M, Svobodova J, Parizkova J. Serum leptin levels in patients with heroin addiction, the effect of one year of methadone substitution. Vnitr Lek 2004; 50(4)282–285
   PubMedGoogle Scholar
• Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol 2005; 5(1)9–19
   PubMed Web of Science ®Google Scholar
• Rittmaster R S, Cutler G B, Jr, Sobel D O, Goldstein D S, Koppelman M C, Loriaux D L, Chrousos G P. Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab 1985; 60(5)891–895
   PubMed Web of Science ®Google Scholar
• Gerra G, Ceresini S, Esposito A, Zaimovic A, Moi G, Bussandri M, Raggi M A, Molina E. Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: relationship with personality traits. Int Clin Psychopharmacol 2003; 18(5)261–269
   PubMed Web of Science ®Google Scholar
• Kennedy J A, Hartman N, Sbriglio R, Khuri E, Kreek M J. Metyrapone-induced withdrawal symptoms. Br J Addict 1990; 85(9)1133–1140
   PubMedGoogle Scholar
• Wisniewski A B, Brown T T, John M, Cofranceso J, Jr, Golub E T, Ricketts E P, Wand G, Dobs A S. Cortisol levels and depression in men and women using heroin and cocaine. Psychoneuroendocrinology 2006; 31(2)250–255
   PubMed Web of Science ®Google Scholar
• Wen H L, Ho W K, Wong H K, Mehal Z D, Ng Y H, Ma L. Changes in adrenocorticotropic hormone (ACTH) and cortisol levels in drug addicts treated by a new and rapid detoxification procedure using acupuncture and naloxone. Comp Med East West 1979; 6(3)241–245
   PubMedGoogle Scholar
• Vescovi P P, Gerra G, Maninetti L, Pedrazzoni M, Michelini M, Pioli G, Girasole G, Caccavari R, Maestri D, Passeri M. Metyrapone effects on beta-endorphin, ACTH and cortisol levels after chronic opiate receptor stimulation in man. Neuropeptides 1990; 15(3)129–132
   PubMed Web of Science ®Google Scholar
• Kiefer F, Horntrich M, Jahn H, Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency?. Psychopharmacology (Berl) 2002; 162(4)433–437
   PubMed Web of Science ®Google Scholar
• Wen H L, Ho W K, Ling N, Mehal Z D, Ng Y H. Immunoassayable beta-endorphin level in the plasma and CSF of heroin addicted and normal subjects before and after electroacupuncture. Am J Chin Med 1980; 8(1–2)154–159
   PubMed Web of Science ®Google Scholar
• Ho W K, Wen H L, Ling N. Beta-endorphin-like immunoactivity in the plasma of heroin addicts and normal subjects. Neuropharmacology 1980; 19(1)117–120
   PubMed Web of Science ®Google Scholar
• Wen H L, Ho W K, Wen P Y. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol 1984; 100(2)155–162
   PubMed Web of Science ®Google Scholar
• Su C Y, Lin C S, Peng C, Cheng C S, Loh H H, Li C H, Way E L. Suppression of morphine abstinence in heroin addicts by beta-endorphin. Adv Biochem Psychopharmacol 1980; 22: 503–509
   PubMedGoogle Scholar
• Cavagnini F, Croci M, Putignano P, Petroni M L, Invitti C. Glucocorticoids and neuroendocrine function. Int J Obes Relat Metab Disord 2000; 24(Suppl 2)S77–79
   PubMed Web of Science ®Google Scholar
• Clausen T R, Moller M, Woldbye D P. Inhibitory effect of neuropeptide Y on morphine withdrawal is accompanied by reduced c-fos expression in specific brain regions. J Neurosci Res 2001; 64(4)410–417
   PubMed Web of Science ®Google Scholar
• Olson V G, Griner N B, Heusner C L, Palmiter R D. Lack of neuropeptide Y attenuates the somatic signs of opiate withdrawal. Synapse 2006; 60(7)553–556
   PubMed Web of Science ®Google Scholar